Actinogen Limited announced Dr. Bill Ketelbey has been appointed as Chief Executive Officer. Prior to joining Actinogen Medical, Dr. Ketelbey was Regional Vice President of Medical Affairs for Pfizer's Primary Care Business Unit for Australia and New Zealand, Japan, Canada, Korea and Country Medical Director for Pfizer Australia and New Zealand. At Pfizer, Dr. Ketelbey was responsible for leading the development of numerous market leading medicines in a broad range of therapeutic areas, including in Alzheimer's Disease.

As Actinogen Medical's CEO, he will be responsible for overseeing the development and commercialization of XanamemTM for the treatment of Alzheimer's disease and mild cognitive impairment.